Using Furosemide to Predict Kidney Injury Progression in ICU Patients
The Role of Furosemide Stress Test in Predicting Acute Kidney Injury Progression and Need for Renal Replacement Therapy in Patients Followed in the Intensive Care Clinic
This study is testing if a special kidney test using furosemide can help doctors predict how kidney injury will progress in critically ill patients and when to start treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 140 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Gulhane Training and Research Hospital Government |
| Locations | 1 site (Ankara, keçiören) |
| Trial ID | NCT06765031 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility of the furosemide stress test (FST) as a predictive tool for the progression of acute kidney injury (AKI) in critically ill patients. It aims to determine the optimal timing for initiating renal replacement therapy (RRT) by analyzing various biomarkers from patients' blood and urine samples. The study focuses on patients who meet specific KDIGO AKI criteria and have sufficient fluid volume. By assessing the effectiveness of FST, the research seeks to improve decision-making regarding patient care in the intensive care unit.
Who should consider this trial
Good fit: Ideal candidates include critically ill patients over 18 years old who meet KDIGO AKI stage 1 and 2 criteria within the first 24 hours of hospitalization.
Not a fit: Patients with advanced AKI (KDIGO stage 3), those requiring urgent RRT, or with certain comorbidities such as chronic kidney disease will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to better management of AKI and potentially reduce the need for invasive renal replacement therapy.
How similar studies have performed: While the use of furosemide in AKI management has been explored, the specific application of the furosemide stress test as a predictive tool is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Those who meet KDIGO AKI stage 1 and stage 2 criteria in the first 24 hours 2. Those with sufficient fluid volume (CVP≥6 cmH20) 3. Female and male patients over the age of 18 will be included in the study Exclusion Criteria: 1. Pregnant patients 2. Hospitalization due to intoxication 3. Liver or kidney transplant 4. Glomerular filtration rate below 30 ml/min/1.73m2 5. Active bleeding 6. Patients with obstructive uropathy 7. Patients in need of urgent RRT (K≥6.6 meq/L, pH\<7.15, pulmonary edema due to fluid overload, uremic complications) 8. Patients evaluated as KDIGO AKI stage 3 9. Patients who have received RRT in the last 30 days 10. Patients with CKD diagnosis 11. Patients with pulmonary embolism 12. Hypoalbuminemia≥2.5 g/dl, 13. Patients receiving cephalosporin treatment will be excluded from the sample.
Where this trial is running
Ankara, keçiören
- Gulhane Training and Research Hospital — Ankara, keçiören, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: mete e erdemir, intensive care specialist
- Email: meteerdemir@hotmail.com
- Phone: +905066321175
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.